New clinical data on weight management will be revealed at SupplySide West 2018 after Fytexia extended its range of clinically proven weight management solutions with DNF-10.
Obtained from a screening of small molecular weight peptides after proteolysis of Saccharomyces cerevisiae, DNF-10 addresses weight management through a regulation of the mediators of satiety. The low molecular weight peptides (<10kDa) from DNF-10 lower the hypothalamic expression of neuropeptide Y and downregulate ghrelin, our inner hunger-promoter. Over the long term, DNF-10 is proven to also modulate the secretion of leptin, a satiety hormone secreted by our fat cells.
Clinical studies show that a daily intake of 500 mg of DNF-10 significantly decreases the caloric intake of supplemented subjects by 200kcal/day after the first week to reach a total reduction in caloric intake of 600 kcal/day after 2 months. This lower intake of food results in significant body weight loss after four weeks. Measured with computed tomography, the weight loss is from a reduction in fat mass.
Four published clinical studies on a total 135 subjects are available to support these results.
Water-soluble and heat-resistant, DNF-10 is recommended at a dosage of 500 mg/day for the formulation of dietary supplements and functional foods.
solutions, led by the flagship ingredient Sinetrol, a natural fat-burner supported with three clinical studies.
Fytexia will be exhibiting at SupplySide West 8-9 November at booth #4251.
For more details contact Fytexia at lnogier@fytexia.com
